Integrin Receptor Imaging of Breast Cancer Using 99Mtc-3Prgd2 SPECT/CT: Compared with 18F-FDG PET/CT

Xiaona Jin,Ying Xu,Ximin Shi,Bing Jia,Qiang Sun,Zhaohui Zhu,Wenhong Fan,Fang Li
2013-01-01
Abstract:74 Objectives To evaluate 99mTc-3PRGD2, a new tracer targeting integrin αvβ3 receptor, in imaging of breast cancer via SPECT/CT, compared with 18F-FDG PET/CT of the same patients. Methods Thirty-nine female patients with 66 suspicious breast lesions were enrolled with informed consent. Whole-body planar scanning and chest SPECT/CT were performed one hour after intravenous injection of 11.1 MBq/kg 99mTc-3PRGD2. 18F-FDG PET/CT were underwent within one week for comparison. Results The tumor to normal breast ratios (T/B) of 99mTc-3PRGD2 were significantly higher in breast malignancies (3.2±1.9, n=34) than those of benign lesions (1.7±0.7, n=32; P=0.0005). There were significant correlations between the 99mTc-3PRGD2 accumulation and the 18F-FDG uptake in both malignancies and benign lesions (P=0.004 and 0.003, respectively). 99mTc-3PRGD2 SPECT/CT detected 38/40 of the true positive lymph-node metastasis on PET/CT. Receiver operating characteristic (ROC) analysis and z statistics showed that 99mTc-3PRGD2 SPECT/CT had similar efficacy as 18F-FDG PET/CT in diagnosis of breast cancer (P=0.154). The 99mTc-3PRGD2 uptake in the breast malignancies with lymph-node metastasis (patient number=15) were significantly higher than those without lymph-node involvement (patient number =12) (P=0.021), and the 99mTc-3PRGD2 accumulation in the primary tumor had significant correlation with those of the metastatic lymph-nodes (r=0.810, P=0.005). While for the 18F-FDG uptake, there were no significant difference of uptake between the breast tumors with and without lymph-node involvement (P=0.263) and between the primary tumors and involved lymph-nodes (P=0.09). Conclusions 99mTc-3PRGD2 SPECT/CT has similar efficacy as 18F-FDG PET/CT in differentiation of breast tumor and detection of lymph-node metastasis. Moreover, it seems to have a preferable advantage over 18F-FDG PET/CT by indicating the metastatic characteristcs of breast cancer.
What problem does this paper attempt to address?